NEW YORK, NY / ACCESSWIRE / February 5, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Penumbra, Inc. (NYSE:PEN)
CONTACT JAKUBOWITZ ABOUT PEN:
https://claimyourloss.com/securities/penumbra-inc-loss-submission-form/?id=12726&from=1
Class Period: August 3, 2020 - December 15, 2020
Lead Plaintiff Deadline: March 16, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of the Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and (4) as a result, Penumbra's public statements as set forth above were materially false and misleading at all relevant times.
GoodRx Holdings, Inc (NASDAQ:GDRX)
CONTACT JAKUBOWITZ ABOUT GDRX:
https://claimyourloss.com/securities/goodrx-holdings-inc-loss-submission-form/?id=12726&from=1
Class Period: September 23, 2020 - November 16, 2020
Lead Plaintiff Deadline: February 16, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.
QuantumScape Corporation f/k/a Kensington Capital Acquisition Corp. (NYSE:QS)
CONTACT JAKUBOWITZ ABOUT QS:
https://claimyourloss.com/securities/quantumscape-corporation-f-k-a-kensington-capital-acquisition-corp-loss-submission-form/?id=12726&from=1
Class Period: November 27, 2020 - December 31, 2020
Lead Plaintiff Deadline: March 8, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company's purported success related to its solid-state battery power, battery life, and energy density were significantly overstated; (2) that the Company is unlikely to be able to scale its technology to the multi-layer cell necessary to power electric vehicles; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law